Veraxa Biotech AG develops next-generation antibody-based therapeutics for cancer, including bispecific antibody-drug conjugates and BiTAC formats for T-cell engagement. Its discovery platform leverages scientific advances from the European Molecular Biology Laboratory together with proprietary technologies for functional antibody screening and bioconjugation. The company is advancing a pipeline of candidates aimed at widening the therapeutic window and enhancing safety for patients with solid tumors and blood cancers.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2023 | 0 | — | -16.5 | — |
| 2024 | 0 | — | -28.1 | — |
| 2025 | 0 | — | -66.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Xsolla SPAC 1 (XSLL), LCNB Corp. (LCNB), Western New England Bancorp, Inc. (WNEB), Entrada Therapeutics, Inc. (TRDA), Cantor Equity Partners I, Inc. (CEPO), First Northern Community Bancorp (FNRN)